NEWFOUNDLAND AND LABRADOR

FIRAZYR is covered by Newfoundland and Labrador Prescription Drug Program (Special Authorization)

Eligibility

For FIRAZYR to be eligible for coverage by the Newfoundland and Labrador Prescription Drug Program, prescribers must submit a request for special authorization and approval must be in place before the patient fills the prescription. Deductibles may apply. For more information concerning the reimbursement process, contact OnePath®.

Reimbursement Criteria

We are pleased to inform you that FIRAZYR (icatibant acetate) is reimbursed in Newfoundland and Labrador for your hereditary angioedema (HAE) patients who meet the following criteria:

For the treatment of acute attacks of HAE in adults with lab confirmed C1-esterase inhibitor deficiency (type I or type II) under the following conditions:

  • Treatment of non-laryngeal attacks of at least moderate severity, OR
  • Treatment of acute laryngeal attacks

Clinical Notes:

  • Coverage is limited to a single dose for self-administration per attack
  • Must be prescribed by physicians with experience in the treatment of HAE

Claim Notes:

  • Maximum of two doses on hand at any time

OnePath® Patient Support Program will help navigate insurance coverage and access reimbursement to medication through private and public insurance companies.

Find Out More

Source: Newfoundland and Labrador Health and Community Services. Firazyr Coverage. March 2022.
https://www.health.gov.nl.ca/health/prescription/newformulary.asp